MedPath

The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

Not Applicable
Conditions
type 2 diabetes mellitus hypertension
Registration Number
JPRN-UMIN000004925
Lead Sponsor
Department of Internal Medicine, School of Medicine, Keio University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
70
Inclusion Criteria

Not provided

Exclusion Criteria

1. type 1 diabetes mellitus 2. Patients who take both ACE inhibitor and ARB 3. Ptients who have allergy to the study drugs 4. Severe hypertension (180/110 mmHg or higher) 5. Pregnant women, women who want to be pregnant 6. Patients taking cyclosporine 7. Sever liver dysfunction (GOT>80 IU/L, GPT>80 IU/L), renal dysfunction (Cr>1.5(male), 1.4 (female) mg/dl)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The value of HbA1c at the endopoitn of the trial
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath